DocDollars

Glaxosmithkline, LLC.

PA · United States · Reporting entity ID 100000005449

Total reported 2019–2025
$1.52B
#13 of 2,960 reporting companies — 1.8% of all reported industry payments
$171.3M in general payments across 2,231,988 records, plus $1.35B in research funding across 142,406 records.

How it breaks down

General payments $171,319,977
Research funding $1,345,363,423

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Glaxosmithkline, LLC. reported $1.52B to US doctors and teaching hospitals from 2019 to 2025, ranking #13 of 2,960 reporting companies. 89% of that was research funding and 11% general payments such as consulting, speaking, food and travel. 2,231,988 general payment records and 142,406 research records were filed.

Common questions about Glaxosmithkline, LLC.

How much has Glaxosmithkline, LLC. paid US doctors?

Glaxosmithkline, LLC. reported $1,516,683,400 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $171,319,977 in general payments, $1,345,363,423 in research funding.

How does Glaxosmithkline, LLC. rank among drug and device companies?

It ranks #13 of 2,960 reporting entities by total reported value, about 1.8% of all industry payments in the dataset.

Does a payment from Glaxosmithkline, LLC. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.